ATE470445T1 - Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) - Google Patents

Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)

Info

Publication number
ATE470445T1
ATE470445T1 AT08004276T AT08004276T ATE470445T1 AT E470445 T1 ATE470445 T1 AT E470445T1 AT 08004276 T AT08004276 T AT 08004276T AT 08004276 T AT08004276 T AT 08004276T AT E470445 T1 ATE470445 T1 AT E470445T1
Authority
AT
Austria
Prior art keywords
ranolazine
eads
depolarization
medication
produce
Prior art date
Application number
AT08004276T
Other languages
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Application granted granted Critical
Publication of ATE470445T1 publication Critical patent/ATE470445T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08004276T 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) ATE470445T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
ATE470445T1 true ATE470445T1 (de) 2010-06-15

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03723907T ATE397932T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien
AT08004276T ATE470445T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03723907T ATE397932T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Country Status (19)

Country Link
US (2) US20030220344A1 (de)
EP (3) EP1490066B1 (de)
JP (1) JP4608217B2 (de)
KR (2) KR20040099395A (de)
CN (2) CN101843619A (de)
AT (2) ATE397932T1 (de)
AU (3) AU2003230810B2 (de)
CA (1) CA2481192C (de)
CY (1) CY1110400T1 (de)
DE (2) DE60332975D1 (de)
DK (2) DK1930007T3 (de)
ES (2) ES2304507T3 (de)
IL (1) IL197406A0 (de)
MX (1) MXPA04009637A (de)
NO (1) NO330953B1 (de)
NZ (1) NZ535610A (de)
PT (2) PT1490066E (de)
SI (2) SI1930007T1 (de)
WO (1) WO2003086401A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CN100551370C (zh) * 2002-05-21 2009-10-21 Cv医药有限公司 雷诺嗪在制备治疗糖尿病的药物组合物中的应用
KR20060124646A (ko) * 2003-12-18 2006-12-05 씨브이 쎄러퓨틱스, 인코포레이티드 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물
MX2007005367A (es) * 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
JP2008526879A (ja) * 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
EP1879583A2 (de) * 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Chininformulierungen
CN100522169C (zh) * 2005-07-04 2009-08-05 齐鲁制药有限公司 盐酸雷诺嗪缓释制剂及其制备方法
JP2010514696A (ja) * 2006-12-21 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心血管症状の低減
CA2678515A1 (en) 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
KR20110013348A (ko) * 2008-02-06 2011-02-09 길리애드 사이언시즈, 인코포레이티드 통증 치료를 위한 라놀라진의 용도
CA2735653A1 (en) * 2008-09-04 2010-03-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US20150148352A1 (en) * 2012-08-14 2015-05-28 Cellixbio Private Limited Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
HK1219893A1 (zh) 2013-08-01 2017-04-21 吉利德科学公司 治療長qt綜合征的化合物和方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (de) 2014-09-29 2020-03-18 Cellix Bio Private Limited Verbindungen und zusammensetzungen zur behandlung multipler sklerose
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
KR101617683B1 (ko) 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN116808039A (zh) * 2023-03-27 2023-09-29 河南中医药大学第一附属医院 青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) * 2023-07-06 2025-01-09 The General Hospital Corporation Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DK0407780T3 (da) * 1989-06-23 1996-09-30 Syntex Inc Ranolazin og beslægtede piperaziner til anvendelse i behandling af væv, der har været udsat for fysisk eller kemisk skade
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
CA2172513C (en) * 1993-09-24 2008-01-08 Bernard A. Macleod Aminocyclohexylesters and uses thereof
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP1259230A2 (de) * 2000-02-18 2002-11-27 Cv Therapeutics, Inc. Partielle inhibitoren der fettsäureoxidation zur behandlung des kongestiven herzversagens
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CN103356996A (zh) * 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
AU2009201065A1 (en) 2009-04-09
PT1930007E (pt) 2010-08-17
DE60321550D1 (de) 2008-07-24
DE60332975D1 (de) 2010-07-22
CN101843619A (zh) 2010-09-29
ES2345573T3 (es) 2010-09-27
DK1490066T3 (da) 2008-10-13
EP1490066B1 (de) 2008-06-11
US20030220344A1 (en) 2003-11-27
JP2005528393A (ja) 2005-09-22
ES2304507T3 (es) 2008-10-16
KR20100119804A (ko) 2010-11-10
SI1490066T1 (sl) 2008-10-31
HK1120390A1 (en) 2009-04-03
IL197406A0 (en) 2011-07-31
AU2003230810B2 (en) 2009-02-26
AU2003230810A1 (en) 2003-10-27
ATE397932T1 (de) 2008-07-15
JP4608217B2 (ja) 2011-01-12
PT1490066E (pt) 2008-07-22
EP2198866A1 (de) 2010-06-23
CN1646127A (zh) 2005-07-27
EP1930007A1 (de) 2008-06-11
AU2011202135A1 (en) 2011-05-26
EP1490066A1 (de) 2004-12-29
NO20044783L (no) 2004-11-03
CA2481192C (en) 2012-07-03
CA2481192A1 (en) 2003-10-23
AU2009201065B2 (en) 2011-07-21
NZ535610A (en) 2006-05-26
NO330953B1 (no) 2011-08-22
KR20040099395A (ko) 2004-11-26
CY1110400T1 (el) 2015-04-29
WO2003086401A1 (en) 2003-10-23
EP1930007B1 (de) 2010-06-09
CN100548300C (zh) 2009-10-14
DK1930007T3 (da) 2010-08-30
SI1930007T1 (sl) 2010-08-31
MXPA04009637A (es) 2005-07-14
US20100004255A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
DE60332975D1 (de) Verwendung von Ranolazin zur Herstellung eines Medikaments zur Behandlung von frühen Nachdepolarisationen (EADs)
GB0223038D0 (en) Therapeutic compounds
ATE517658T1 (de) Arrythmie-klassifizierung und therapiewahl
Neganova et al. Mechanisms of antioxidant effect of natural sesquiterpene lactone and alkaloid derivatives
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
ATE451091T1 (de) Kosmetisches peeling-verfahren unter verwendung von harnstoff
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
DE50213170D1 (de) Verwendung eines Mittel zur Therapie der Herzhypertrophie
WO2004044144A3 (en) Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
ATE380551T1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
CO5170445A1 (es) Nuevos compuestos morfinoides,su preparacion y utilizacion
DE602004016292D1 (de) Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE60336275D1 (de) Verfahren zur Herstellung von 3-(1,3-Dihydroimidazol-2-thion-1-yl)-chromanen und thiochromanen als Dopamin-beta-hydroxylase Inhibitor
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
CY1115214T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
DE60033633D1 (de) Kit aus polyakrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und der diabetes mellitus
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
ATE376914T1 (de) Verwendung einer wässrigen lösung mit einem oder mehreren bifluoriden zur verbesserung des trocknungsprozesses von frischholz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1930007

Country of ref document: EP